GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Oramed Pharmaceuticals
Oramed Pharmaceuticals develops technology for the oral delivery of drugs typically administered by injection, such as insulin. Its stock price is a venture capital bet on this "holy grail" of pharmaceuticals. The chart reflects the binary risks of clinical trials.
Share prices of companies in the market segment - Pharma other
Oramed Pharmaceuticals is an Israeli company developing technology for the oral delivery of drugs currently administered only by injection, such as insulin. We classify it under "Other Pharmaceuticals." The chart below shows the dynamics of this innovative segment.
Broad Market Index - GURU.Markets
Oramed Pharmaceuticals is an Israeli company pioneering the development of oral protein delivery technology, specifically insulin. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how investors are valuing this breakthrough technology.
Change in the price of a company, segment, and market as a whole per day
ORMP - Daily change in the company's share price Oramed Pharmaceuticals
For Oramed Pharmaceuticals, which develops oral insulin, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to biotech risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma other
Oramed Pharmaceuticals Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ORMP, which focuses on oral drug delivery, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Oramed Pharmaceuticals develops oral delivery technology for drugs currently administered only by injection, such as insulin. The company's shares are driven by news of clinical trials. This high volatility is part of the market dynamics driven by hopes for new drugs.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Oramed Pharmaceuticals
For Oramed Pharmaceuticals, the year-over-year trend is a story of the failure of its flagship development, oral insulin. Its market capitalization change over the past 12 months reflects the failure of key clinical trials, which forced the company to seek new strategic directions and use its remaining cash for recovery.
Annual dynamics of market capitalization of the market segment - Pharma other
Oramed Pharmaceuticals Inc. is an Israeli biotech company developing oral delivery technology for drugs typically administered by injection, such as insulin. Its stock price is highly volatile, reflecting investor confidence in its breakthrough potential and clinical trial results.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Oramed, with its attempt to create insulin in tablets, is a high-risk, high-potential story. Its share price (ADR) is entirely dependent on the results of clinical trials. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become a reality.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing an oral drug delivery technology, specifically insulin. Its monthly progress is a chronicle of its clinical trials. The results of these studies are binary events: success could lead to a revolution in diabetes treatment, while failure could lead to a sharp decline.
Monthly dynamics of market capitalization of the market segment - Pharma other
Oramed Pharmaceuticals is a pioneer in developing technologies for the oral delivery of drugs traditionally administered by injection, particularly insulin. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its revolutionary platform is progressing through clinical trials, with the potential to transform diabetes treatment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Oramed Pharmaceuticals develops oral drug delivery technology. It's a biotech company whose value is entirely dependent on the success of clinical trials. The chart shows monthly fluctuations, which reflect not overall market sentiment, but investor confidence in its breakthrough technology platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Oramed Pharmaceuticals
Oramed Pharmaceuticals, an Israeli company developing technology for the oral delivery of drugs (in tablets) typically administered by injection, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials, particularly in the field of diabetes.
Weekly dynamics of market capitalization of the market segment - Pharma other
Oramed Pharmaceuticals is developing oral drug delivery technology, such as insulin. This represents a potential breakthrough, but carries significant risks. This chart compares the market reaction to Oramed's news with overall trends in the pharmaceutical sector and helps us understand the investor confidence in its unique technology platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Oramed Pharmaceuticals develops oral drug delivery technology. Its shares follow the rhythm of development news. The chart shows how Oramed's performance is unaffected by general market fluctuations, driven by its unique scientific and commercial news.
Market capitalization of the company, segment and market as a whole
ORMP - Market capitalization of the company Oramed Pharmaceuticals
Oramed's stock chart is the financial history of a decades-long dream of creating insulin tablets. Its market capitalization reflects the hopes and disappointments of this daunting task. Its volatility directly mirrors the results of clinical trials, where every step could either bring a revolution in diabetes treatment closer or delay it indefinitely.
ORMP - Share of the company's market capitalization Oramed Pharmaceuticals within the market segment - Pharma other
Oramed Pharmaceuticals' stake in the pharmaceutical sector is a bet on revolutionizing drug delivery. The company is developing technology for orally administering drugs currently available only as injections, such as insulin. Its market share reflects the potential for this breakthrough.
Market capitalization of the market segment - Pharma other
Oramed Pharmaceuticals develops technology for the oral delivery of drugs typically administered by injection, such as insulin. The chart below shows the market capitalization of the entire pharmaceutical industry. Its dynamics provide a backdrop for the valuation of Oramed, whose technology has the potential to be revolutionary.
Market capitalization of all companies included in a broad market index - GURU.Markets
Oramed Pharmaceuticals develops technology for the oral delivery of drugs typically administered by injection, such as insulin. Its market capitalization is a bet on a breakthrough in drug delivery. The chart below shows the economic weight of companies solving this complex problem.
Book value capitalization of the company, segment and market as a whole
ORMP - Book value capitalization of the company Oramed Pharmaceuticals
For Oramed Pharmaceuticals, which develops oral insulin, book value is its capital. The chart below tells the story of the financial resources needed to conduct very expensive and risky clinical trials. Its dynamics are the pulse of its ambitious scientific project.
ORMP - Share of the company's book capitalization Oramed Pharmaceuticals within the market segment - Pharma other
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs typically administered by injection. Its value lies in its scientific platform. The share of tangible assets will be minimal, typical for an R&D company whose primary capital is intellectual property.
Market segment balance sheet capitalization - Pharma other
Oramed Pharmaceuticals is developing an oral insulin delivery technology. Its value lies in its patents and clinical data, not its manufacturing facilities. This is a classic "light" biotech model. The chart below illustrates how capital-intensive the pharmaceutical industry as a whole is and allows one to appreciate this R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Oramed Pharmaceuticals' balance sheet consists of intellectual property rights for oral delivery technology for insulin and other proteins typically administered by injection. The company's assets represent capital invested in an attempt to revolutionize diabetes treatment by eliminating the need for injections.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Oramed Pharmaceuticals
Oramed Pharmaceuticals develops technology for the oral delivery of drugs typically administered by injection (such as insulin). The company has no significant tangible assets. Its market capitalization is a bet on a breakthrough in this "holy grail" of pharmaceuticals. The chart reflects the high risk and potentially enormous reward in case of success.
Market to book capitalization ratio in a market segment - Pharma other
Oramed Pharmaceuticals develops technology for the oral delivery of drugs typically administered by injection, such as insulin. The company's value depends almost entirely on the success of this breakthrough platform. The chart shows the significant premium the market is placing on its potential to transform the pharmaceutical market.
Market to book capitalization ratio for the market as a whole
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs typically administered by injection, such as insulin. The chart shows how the market values this potentially revolutionary technology. The company's market capitalization is a bet on the success of its clinical trials, which could change the lives of millions of patients and generate huge revenues.
Debts of the company, segment and market as a whole
ORMP - Company debts Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing technology for the oral delivery of drugs traditionally administered by injection, such as insulin. This is a disruptive but risky field. This chart shows how the company is raising capital to fund its lengthy and expensive clinical trials.
Market segment debts - Pharma other
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs currently administered by injection, such as insulin. This is a potentially revolutionary technology in pharmaceuticals. The chart provides insight into the financial norms of the industry, where companies are raising significant capital to conduct large-scale clinical trials of their breakthrough platforms.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing a revolutionary technology—insulin in tablets. This is a complex scientific endeavor, requiring years of research and testing. This chart shows the company's reliance on debt financing to implement its ambitious project. It directly indicates the financial risks involved in achieving a potential breakthrough.
Market segment debt to market segment book capitalization - Pharma other
Developing oral forms of drugs typically administered by injection (such as insulin), like Oramed's, could revolutionize medicine. This chart shows how the biotech sector is funding its breakthrough technologies. It allows us to appreciate how Oramed Pharmaceuticals' financial model differs from other companies working on drug delivery systems.
Debt to book value of all companies in the market
Oramed Pharmaceuticals is developing an oral form of insulin—a potentially revolutionary technology. Decades of research require massive investment. The chart shows how the debt taken on to finance this ambitious goal compares to the overall capital structure of the market.
P/E of the company, segment and market as a whole
P/E - Oramed Pharmaceuticals
This valuation for Oramed Pharmaceuticals, a company developing oral delivery technology for drugs typically administered by injection (such as insulin), reflects confidence in its breakthrough technology. The company's valuation is based on expectations of successful clinical trials and the potential to revolutionize diabetes treatment.
P/E of the market segment - Pharma other
This indicator represents the average valuation for the biotech sector in which Oramed Pharmaceuticals operates. It reflects the overall level of hope and expectation in this cutting-edge field of science. The chart serves as a barometer of investor confidence in the future of oral drug delivery technologies.
P/E of the market as a whole
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs typically administered by injection, such as insulin. This could revolutionize the lives of millions of patients. This chart illustrates the market's interest in breakthrough technologies. It helps us understand whether the market believes Oramed can overcome the enormous scientific challenges and the level of risk inherent in its current valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs currently administered by injection, specifically insulin. The company's future depends entirely on the success of this revolutionary platform in clinical trials. This graph reflects the high, yet speculative, expectations of investors regarding the potential paradigm shift in diabetes treatment.
%20P%2FE%20Oramed%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Oramed-Pharmaceuticals&v=1772513617554 "Chart of the company's future (projected) P/E Oramed Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma other
Oramed Pharmaceuticals is developing a technology for the oral (capsule) delivery of drugs traditionally administered only by injection, such as insulin. This could be a breakthrough for millions of patients. The chart reflects expectations for the biotech sector, helping to assess the market's confidence in this revolutionary, yet risky, technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772513617568 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs currently administered only by injection, such as insulin. This is a potentially revolutionary development. This graph of overall expectations demonstrates investor appetite for breakthrough ideas. Market optimism is essential for funding such ambitious projects, which have the potential to change the lives of millions of people.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513617574 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs currently administered by injection, specifically insulin. This chart shows the financial costs of this revolutionary but risky research. The success or failure of key clinical trials will determine whether the company will ever turn a profit.
Profit of companies in the market segment - Pharma other
The Herzfeld Caribbean Basin Fund is a closed-end fund that invests in companies the manager believes will benefit from economic growth in the Caribbean. This chart shows how the performance of such highly specialized funds depends not only on global trends but also on specific political and economic events in a particular region.
Overall market profit
Oramed Pharmaceuticals is developing technology for the oral delivery of drugs currently administered only by injection, such as insulin. The company's success hinges on the results of its clinical trials. If successful, its technology could change the lives of millions of people and create enormous value, regardless of overall economic trends.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing technology for the oral delivery of drugs currently administered only by injection, primarily insulin. The company's profit forecast is entirely dependent on the success of its clinical trials. This chart reflects analysts' speculative expectations regarding the potential for a breakthrough in diabetes treatment by changing the way insulin is administered.
%20profit%20of%20the%20company%20Oramed%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Oramed-Pharmaceuticals&v=1772513617614 "Graph of future (projected) profit of the company Oramed Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma other
Oramed Pharmaceuticals is developing technology for the oral delivery of drugs currently administered only by injection, such as insulin. This is a potentially revolutionary approach to diabetes treatment. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the enormous potential and high risks associated with developing breakthrough drug delivery platforms.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772513617641 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Oramed Pharmaceuticals develops technologies for the oral delivery of drugs typically administered by injection, such as insulin. This is a potentially revolutionary technology. General market expectations, illustrated in this chart, influence investor willingness to finance such long-term and risky pharmaceutical projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513617647 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Oramed Pharmaceuticals
Oramed Pharmaceuticals develops technology for the oral delivery of drugs currently administered only by injection, primarily insulin. The company has no approved products or revenue. The chart reflects investors' high hopes for a breakthrough that could radically change the lives of millions of diabetics, but also the high risk of clinical failure.
P/S market segment - Pharma other
Oramed Pharmaceuticals is a clinical-stage pharmaceutical company pioneering the development of oral delivery technology for proteins such as insulin, which are currently administered by injection. This chart shows the average valuation in the sector, providing insight into how the market values the breakthrough potential of Oramed's technology platform.
P/S of the market as a whole
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs traditionally administered by injection, particularly insulin. This could revolutionize diabetics. This chart, showing average valuations, clearly demonstrates the premium investors are willing to place on the potential revenue of this technology, which could change the lives of millions.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing technology for the oral delivery of drugs currently administered by injection, specifically insulin. This chart reflects investors' confidence in the revolutionary potential of this platform. The valuation is based on future revenues that could be generated if clinical trials are successful and oral insulin is approved.
%20P%2FS%20Oramed%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Oramed-Pharmaceuticals&v=1772513617716 "The graph of the company's future (projected) P/S Oramed Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma other
Oramed Pharmaceuticals is developing technology for the oral delivery of drugs currently administered only by injection, such as insulin. The company's success could change the lives of millions of patients. The chart below shows how investors estimate Oramed's potential future sales, reflecting the high expectations for its revolutionary platform.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772513617731 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
This chart reflects hopes for a revolution in drug administration. Oramed Pharmaceuticals is developing technology for the oral delivery of drugs that can currently only be administered by injection, such as insulin. The potential success of their platform could change the lives of millions of patients and create a huge market, fueling long-term investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513617746 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing a revolutionary technology—oral insulin in capsules. Being a company in the clinical development stage, it does not yet have a commercial product and, therefore, no sales revenue. This chart reflects its long research and development journey, where cash flows are tied to investments, not revenue.
Sales of companies in the market segment - Pharma other
Oramed Pharmaceuticals is a pioneer in developing oral delivery technology for drugs currently administered only by injection, primarily insulin. This chart shows the overall revenue of the pharmaceutical industry. It illustrates the enormous potential for the company to create the world's first insulin tablet, changing the lives of millions of diabetics.
Overall market sales
Oramed Pharmaceuticals is an Israeli company developing technology for the oral delivery of drugs currently administered only by injection, specifically insulin. Its valuation is based on the potential of this revolutionary platform. This overall economic climate influences the willingness of investors and large pharmaceutical companies to invest in breakthrough but risky technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing a technology for the oral (capsule) delivery of drugs traditionally administered by injection, such as insulin. The company's future depends on the success of its clinical trials. The chart shows analysts' speculative forecasts, which are betting on a revolution in drug delivery methods.
%20sales%20of%20the%20company%20Oramed%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Oramed-Pharmaceuticals&v=1772513617801 "Schedule of future (projected) sales of the company Oramed Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma other
Oramed Pharmaceuticals is developing technology for the oral delivery of drugs currently administered only by injection, such as insulin. The company's success could revolutionize diabetes treatment. This chart displays projected sales for the entire pharmaceutical sector, highlighting analysts' overall expectations for the diabetes drug market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772513617835 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs currently administered by injection, particularly insulin. The company's success depends entirely on the results of clinical trials. This overall economic climate influences investor sentiment, which is crucial for funding breakthrough but risky medical technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513617887 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs currently administered only by injection, such as insulin. This figure reflects the financial impact of its multi-year research and demonstrates the level of investment in clinical trials, which are key to the commercialization of its breakthrough platform.
Market segment marginality - Pharma other
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs currently administered by injection, such as insulin. The profitability of this breakthrough platform depends on the success of clinical trials. This metric reflects the company's investment in its innovative technology compared to other pharmaceutical companies.
Market marginality as a whole
Oramed Pharmaceuticals is a pioneer in developing oral delivery technology for drugs currently administered only by injection, such as insulin. Their success depends entirely on the results of clinical trials. This overall profitability curve is irrelevant to them; their future is determined by whether they can revolutionize drug delivery.
Employees in the company, segment and market as a whole
Number of employees in the company Oramed Pharmaceuticals
Oramed Pharmaceuticals is developing a revolutionary technology for the oral delivery of drugs currently administered only by injection, such as insulin. This chart shows the size of the scientific team leading this complex development. The staff dynamics reflect progress in multi-year clinical trials and investment in the platform.
Share of the company's employees Oramed Pharmaceuticals within the market segment - Pharma other
Oramed Pharmaceuticals is developing technology for the oral delivery of drugs currently administered only by injection, such as insulin. This chart shows the concentration of unique scientists in the field of pharmaceutical technology. The proportion of such specialists reflects its ambitious goal: to revolutionize diabetes treatment.
Number of employees in the market segment - Pharma other
Oramed Pharmaceuticals is a company developing oral delivery technology for drugs currently administered by injection, such as insulin. This chart shows overall employment in the pharmaceutical sector. It illustrates the industry's commitment to creating more patient-friendly treatments, which could fundamentally change the market for many drugs.
Number of employees in the market as a whole
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs currently administered only by injection, such as insulin. This could revolutionize diabetes treatment. This graph illustrates the labor market, where biotech companies solving such ambitious problems are attracting significant investment and creating highly skilled jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals is a pioneer in developing oral delivery technology for drugs currently administered only by injection, such as insulin. This chart shows the company's enormous market capitalization per employee, typical for a biotech company with a breakthrough platform. The market evaluates the technology's potential to transform multi-billion dollar markets, not the current performance of a small team.
%20of%20the%20company%20Oramed%20Pharmaceuticals%20(ORMP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Oramed-Pharmaceuticals-ORMP&v=1772513618173 "Chart of market capitalization per employee (in thousands of dollars) of the company Oramed Pharmaceuticals (ORMP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Oramed Pharmaceuticals is developing a technology for the oral delivery of drugs traditionally administered by injection, such as insulin. This is a potentially revolutionary technology. This indicator reflects the enormous value the market sees in their scientific platform. A high indicator reflects the bet that their technology will be a game-changer for the pharmaceutical industry.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772513618177 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Oramed Pharmaceuticals develops technology for the oral delivery of drugs currently administered by injection, such as insulin. The company's valuation reflects a bet on this technological breakthrough. The high market capitalization per employee reflects the platform's enormous potential to change the lives of millions of patients if it proves effective.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513618192 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals is a biotech company that has been working for decades to develop an oral insulin capsule. It's a classic R&D business with a binary outcome. This graph shows the net loss (investment in clinical research) per employee engaged in this long-term research endeavor.
%20Chart%20Oramed%20Pharmaceuticals%20(ORMP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Oramed-Pharmaceuticals-ORMP&v=1772513618214 "Company Profit Per Employee (in thousands of dollars) Chart Oramed Pharmaceuticals (ORMP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Oramed Pharmaceuticals is working on a revolutionary technology—creating insulin in tablets. For a company in the R&D stage, this metric is irrelevant. The graph represents the industry norm. If successful, Oramed will be able to license its technology, which would generate colossal profits with minimal staff, far exceeding any industry benchmark.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772513618241 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Oramed Pharmaceuticals (ORMP) is tackling a complex challenge: creating an oral form of insulin (a pill instead of a shot) and other medications currently administered by injection. This is revolutionary R&D. This chart illustrates the high cost of such research. The profit per employee is negative until the technology is proven effective.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513618248 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Oramed Pharmaceuticals (ORMP)
For Oramed Pharmaceuticals, a company developing an oral insulin capsule, this chart reflects high expectations, not current sales. The success or failure of its key clinical trial will fundamentally determine future revenue per employee growth, which could be enormous.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Oramed-Pharmaceuticals-ORMP&v=1772513618278 "Sales chart per company employee Oramed Pharmaceuticals (ORMP)")
Sales per employee in the market segment - Pharma other
Oramed Pharmaceuticals is developing a technology for the oral (capsule) delivery of drugs typically administered by injection, such as insulin. This is R&D. This metric reflects the average revenue per employee for the segment. It helps assess how productive the Oramed team is in monetizing its platform compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Oramed (ORMP) is a pharmaceutical company developing technology for the oral (capsule) delivery of drugs typically administered by injection (such as insulin). This indicator is an indicator of the future for them. Zero values currently reflect the R&D stage. An upward trend in the graph will indicate a commercial breakthrough and the success of their unique delivery platform.
Short shares by company, segment and market as a whole
Shares shorted by company Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals suffered a catastrophic failure in its flagship research—an attempt to create insulin in tablets. Now the company is searching for new avenues of development. This chart demonstrates the extreme skepticism of investors, who are betting that after the failure of its core asset, Oramed will be unable to find a new viable direction and is simply a shell.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Oramed-Pharmaceuticals-ORMP&v=1772513618340 "Short Shares Chart for the Company Oramed Pharmaceuticals (ORMP)")
Shares shorted by market segment - Pharma other
Oramed (ORMP) is a pharmaceutical company developing technology for the oral delivery of drugs typically administered by injection, primarily oral insulin. This chart shows the cumulative short position in the speculative pharmaceutical development sector. It reflects the market's deep skepticism about the "holy grail" of oral insulin, a development that has failed many giants.
Shares shorted by the overall market
Oramed (ORMP) is a clinical-stage biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ORMP will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Oramed Pharmaceuticals (ORMP)
Oramed is an Israeli biotech that spent years (and failed) to create the "Holy Grail"—insulin in tablet form. This chart shows the "life after." It measures how much investors believe in their drug delivery (DDP) technology, showing peaks of speculative "overbought" or deep "oversold" levels.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Oramed-Pharmaceuticals-ORMP&v=1772513618396 "RSI 14 indicator chart for the company's stock Oramed Pharmaceuticals (ORMP)")
RSI 14 Market Segment - Pharma other
Oramed (ORMP) — a "pill" instead of an injection (Israel). They are *pioneers* in the development of *oral* (in tablets) *insulin* and other "protein" drugs. The "Pharma Other" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of *the entire* segment. It is vital to understand: is ORMP's growth due to their R&D, or is *the entire* biotech "overheated"?
RSI 14 for the overall market
Oramed (ORMP) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ORMP (Oramed Pharmaceuticals)
Oramed Pharmaceuticals is an Israeli company trying to achieve a breakthrough: creating oral insulin (in capsules), which would eliminate the need for injections for diabetics. This chart shows the speculative average price target from analysts, which depends almost entirely on their belief in the success of this complex technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ORMP-Oramed-Pharmaceuticals&v=1772513618567 "A chart showing analyst consensus forecasts for the expected stock price. ORMP (Oramed Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ORMP (Oramed Pharmaceuticals)
Oramed is an Israeli biotech company that has been working for decades on the "Holy Grail"—creating oral insulin (in tablet form). This chart shows the difference between the current price and the analyst consensus forecast. It reflects their view on the company's value and its technology after recent setbacks in key research.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ORMP-Oramed-Pharmaceuticals&v=1772513618591 "A chart showing the difference between the consensus forecast and the actual stock price. ORMP (Oramed Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Oramed (ORMP) is an Israeli company that has been trying for decades to create the "Holy Grail" of pharmaceuticals: insulin tablets to free diabetics from injections. This chart shows the general expectations of analysts for the pharmaceutical sector. It reflects whether experts believe in a breakthrough in the oral delivery of complex drugs.
Analysts' consensus forecast for the overall market share price
Oramed Pharmaceuticals is an Israeli company that has been working for decades on the "holy grail": creating insulin in tablets. (Note: the trials failed.) This chart shows the overall risk appetite. For Oramed, a company whose value was based on one big idea, overall market optimism (risk appetite) was critical to funding this ambitious but unsuccessful development.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Oramed Pharmaceuticals
Oramed (ORMP) is an Israeli biotech that spent decades chasing the Holy Grail: oral insulin (a pill, not an injection). After failing in that race, they are rebooting. This chart is a story of survival. It reflects their efforts to find new applications for their oral platform using their remaining capital.
AKIMA Market Segment Index - Pharma other
Oramed Pharmaceuticals is an Israeli company trying to achieve a breakthrough: creating oral insulin (in capsules), which would eliminate the need for injections for diabetics. This chart shows the average pharmaceutical sector index. It allows you to assess how Oramed's high-risk but revolutionary project compares to the average pharmaceutical company.
The AKIM Index for the overall market
Oramed Pharmaceuticals is a company developing technologies for the oral delivery of drugs typically administered by injection (such as insulin). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative R&D story, overcoming biological barriers, compares to overall economic trends.
